Orexigen R Therapeutics Announces That Contrave R May Reverse The Incidence Of Metabolic Syndrome

Orexigen Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of central nervous system disorders, including obesity, announced that based on a review of data from its Contrave Phase IIb trial, patients assigned to Contrave dosage groups demonstrated a 50% reduction in the prevalence of metabolic syndrome.

Protect Your Eyes And Attend Professional Fireworks Displays

This year for the 4th of July celebrations, the American Optometric Association (AOA) suggests that families and friends stay away from private firework use and instead enjoy professional displays to protect and preserve eyesight. Each year over the holiday, thousands of adults and children are seriously injured as a result of fireworks and pyrotechnic devices.

DMClinic trade; Offers Effective New Tool To Manage Diabetic Therapy

Standing Stone, Inc., a leader in disease state management solutions, announces the launch of its DMClinic™ software application. DMClinic will help hospitals, clinics and other healthcare facilities manage their inpatient and outpatient diabetic patients.

Merck Sponsors Cinema Ads For HPV Vaccine Gardasil

Merck recently launched a cinema advertising campaign for its human papillomavirus vaccine Gardasil during the opening of the film "Sex and the City, " the Newark Star-Ledger reports. The campaign features a 60-second ad similar to the company's "I Chose" television commercial.

Clinical Study Shows Liraglutide Reduced Blood Sugar, Weight, And Blood Pressure In Patients With Type 2 Diabetes

Data presented at the68thScientific Sessions of the American Diabetes Association (ADA)demonstratedthat once-daily liraglutide when taken alone produced statisticallysignificant improvement in blood sugar (glucose) control in patients withtype 2 diabetes, as compared to glimepiride, a widely used oralanti-diabetic drug (OAD).

Onglyza saxagliptin Demonstrated Significant Reductions In Key Measures Of Glucose Control In Treatment Na Atilde; macr;ve People With Type 2 Diabetes

Results from a 24-week Phase III study presented at the 68th American Diabetes Association Annual Scientific Sessions demonstrated that saxagliptin, a selective, reversible inhibitor of the dipeptidyl peptidase (DPP-4) enzyme in development by Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca.

Knee Pain Offered By Rush University Medical Center

Join orthopedic experts at Rush University Medical Center for a free informational discussion about advanced options in treating chronic knee pain. The free program will be held from 6 to 8:30 p.m., Tuesday, June 24 in Room 542 of the Searle Conference Center, located on the Rush campus, at 1725 W.

Combination Of 'Januvia' With Metformin Improved Markers Of Beta Cell Function And Provided Significant Glucose-lowering At One 1 And 2 Years

New data presented at the American Diabetes Association (ADA) 68th Annual Scientific Sessions showed initial combination therapy with 'Januvia'™ (sitagliptin), a diabetes medicine from Merck & Co., Inc.

Heads Of State Join UN Secretary-General And WHO Director-General To Confront Global Health Threat

When: Monday, 9 June 2008, 3:00 PM to 6:00 PMWhere: UN Conference Room 2, UN Headquarters, New YorkWhat: For the first time ever, heads of government, public health and business leaders, heads of UN agencies and activists will meet at UN Headquarters to confront a global health threat that could undermine investments in life-saving drug treatment for people living with HIV.

Having Heart Surgery? Watch Your Blood Sugar

Nearly half of all heart surgery patients may experience blood sugar levels high enough to require temporary insulin treatment after their operation, even though they've never had diabetes, according to a new study from the University of Michigan Health System.